Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
复制标题
线粒体功能障碍在非酒精性脂肪性肝病中起核心作用。
DOI：
10.3390/ijms23137280
复制
发表时间：
2022-06-30
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
非酒精性脂肪性肝病（NAFLD）是一种影响世界四分之一人口的全球性流行病。NAFLD包括一系列进行性肝病，从脂肪变性到非酒精性脂肪性肝炎（NASH）、纤维化和肝硬化，并可并发肝细胞癌。它与代谢综合征、肥胖和2型糖尿病密切相关，并且已证明代谢失调是其发病机制的核心。近年来，人们认为代谢（功能障碍）相关的脂肪性肝病（MAFLD）比NAFLD更适合描述这种疾病，这使得代谢功能障碍在其发病机制中的重要作用日益得到重视。有强有力的证据表明，线粒体功能障碍在NAFLD的发生和发展中起着重要作用。线粒体脂肪酸氧化受损，以及最近线粒体质量的降低，已被认为在NAFLD的发生和进展中起主要作用。在这篇综述中，我们概述了我们目前对NAFLD的理解，并强调了线粒体功能障碍如何在动物模型和人类受试者中促进其发病机制。进一步，我们讨论了线粒体功能调节NAFLD的证据，并且靶向线粒体是治疗NAFLD/NASH的药物开发的一个有希望的新途径。
Nonalcoholic fatty liver disease (NAFLD) is a global pandemic that affects one-quarter of the world’s population. NAFLD includes a spectrum of progressive liver disease from steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis and can be complicated by hepatocellular carcinoma. It is strongly associated with metabolic syndromes, obesity, and type 2 diabetes, and it has been shown that metabolic dysregulation is central to its pathogenesis. Recently, it has been suggested that metabolic- (dysfunction) associated fatty liver disease (MAFLD) is a more appropriate term to describe the disease than NAFLD, which puts increased emphasis on the important role of metabolic dysfunction in its pathogenesis. There is strong evidence that mitochondrial dysfunction plays a significant role in the development and progression of NAFLD. Impaired mitochondrial fatty acid oxidation and, more recently, a reduction in mitochondrial quality, have been suggested to play a major role in NAFLD development and progression. In this review, we provide an overview of our current understanding of NAFLD and highlight how mitochondrial dysfunction contributes to its pathogenesis in both animal models and human subjects. Further we discuss evidence that the modification of mitochondrial function modulates NAFLD and that targeting mitochondria is a promising new avenue for drug development to treat NAFLD/NASH.
登录
查看更多内容
影响因子：
9.8
作者：
Buzzetti, Elena;Pinzani, Massimo;Tsochatzis, Emmanuel A.
通讯作者：
Tsochatzis, Emmanuel A.
影响因子：
13.5
作者：
Browning, JD;Szczepaniak, LS;Hobbs, HH
通讯作者：
Hobbs, HH
影响因子：
5
作者：
Aharoni-Simon, Michal;Hann-Obercyger, Michal;Tirosh, Oren
通讯作者：
Tirosh, Oren
DOI：
10.1111/j.1440-1746.2005.04233.x
发表时间：
2006-01-01
影响因子：
4.1
作者：
Baba, CS;Alexander, G;Choudhuri, G
通讯作者：
Choudhuri, G
影响因子：
5.9
作者：
Conlon MA;Bird AR
通讯作者：
Bird AR